---
title: "BioMarin EVP, Chief R&D Officer Gregory R Friberg Reports Sale of $302,710.511 in Common Shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306185131.md"
description: "BioMarin Pharmaceutical EVP and Chief R&D Officer Gregory R. Friberg sold 5,147 common shares on Nov. 18, 2026, at $58.813 per share, totaling $302,710.51. Following the transaction, his direct holdings stand at 42,585 shares. The Form 4 filing was dated Nov. 19, 2026."
datetime: "2026-11-19T23:05:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306185131.md)
  - [en](https://longbridge.com/en/news/306185131.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306185131.md)
generator: "portal-rs"
---

# BioMarin EVP, Chief R&D Officer Gregory R Friberg Reports Sale of $302,710.511 in Common Shares

-   BioMarin Pharmaceutical EVP and Chief R&D Officer Gregory R. Friberg sold 5,147 common shares on Nov. 18, 2026. \* The sale price was $58.813 per share, leaving direct holdings of 42,585 shares. \* The Form 4 was dated Nov. 19, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-075143), on November 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [BMRN.US](https://longbridge.com/en/quote/BMRN.US.md)

## Related News & Research

- [BioMarin Pharmaceutical (BMRN) Following Q3 Results And A Guidance Cut Is It A Bargain](https://longbridge.com/en/news/305152575.md)
- [BMRN: Record $1.025B Q3 revenue; FY2026 guidance reset for order timing uncertainty](https://longbridge.com/en/news/304008839.md)
- [ModuleMD Continues to Strengthen Its Position in Allergy EHR Innovation with a New Generation of AI-Powered Technology](https://longbridge.com/en/news/306373301.md)
- [Jabil (JBL) Heads Into Earnings As Its AI Narrative Keeps Undervalued View Alive](https://longbridge.com/en/news/306391907.md)
- [Wall St Week Ahead-'Black Friday' brings consumer spending into focus for AI-rocked market](https://longbridge.com/en/news/306395310.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**